Matches in Nanopublications for { ?s ?p "DDI between Verapamil and Fosamprenavir - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Fosamprenavir is initiated, discontinued or dose changed."@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00661_DB01319 title "DDI between Verapamil and Fosamprenavir - Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Fosamprenavir is initiated, discontinued or dose changed." assertion.